Reflecting on the clinical implications, St-Pierre says that the findings support cautious use of GLP-1 RAs in selected patients with IBD when prescribed for approved metabolic indications, with appropriate counselling and monitoring. At the same time, she noted that the findings highlight substantial evidence gaps and believes future research should move beyond proxy outcomes and incorporate prospective, IBD-specific designs that integrate objective inflammatory measures with robust metabolic phenotyping. Moreover, there should be special considerations on the effects of GLP-1 RAs on body composition of patients with IBD, she adds
None of these outcomes are acceptable when you are injecting something into your body
Some health insurance plans man cover generic Victoza for people with type 2 diabetes
For any of these compounds, check the supplier's reconstitution note before mixing
Never share your pen with others, even if you change the needle
But high here is a bit of an understatement